Last reviewed 2026-04-20 · How we verify

GC4702 lipid suspension

Galera Therapeutics, Inc. · Phase 1 active Small molecule Quality 0/100

GC4702 lipid suspension is a Small molecule drug developed by Galera Therapeutics, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	GC4702 lipid suspension
Sponsor	Galera Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GC4702 lipid suspension CI brief — competitive landscape report
GC4702 lipid suspension updates RSS · CI watch RSS
Galera Therapeutics, Inc. portfolio CI

Frequently asked questions about GC4702 lipid suspension

What is GC4702 lipid suspension?

GC4702 lipid suspension is a Small molecule drug developed by Galera Therapeutics, Inc..

Who makes GC4702 lipid suspension?

GC4702 lipid suspension is developed by Galera Therapeutics, Inc. (see full Galera Therapeutics, Inc. pipeline at /company/galera-therapeutics-inc).

What development phase is GC4702 lipid suspension in?

GC4702 lipid suspension is in Phase 1.

Manufacturer: Galera Therapeutics, Inc. — full pipeline
Compare: GC4702 lipid suspension vs similar drugs
Pricing: GC4702 lipid suspension cost, discount & access